Mitiglinide

Drug Profile

Mitiglinide

Alternative Names: Glinsuna; Glufast; KAD-1229; Kuai ruo tuo; S 21403

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Aichi Gakuin University; Eisai Co Ltd; Elixir Pharmaceuticals; Hikma Pharmaceuticals; JW Pharmaceutical; Kissei Pharmaceutical; Orient Europharma; Takeda; USV
  • Class Amides; Antihyperglycaemics; Butyric acids; Isoindoles; Small molecules
  • Mechanism of Action Insulinotropin agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 17 Jun 2016 Launched for Type-2 diabetes mellitus in Japan (PO; Fast dissolve)
  • 08 Jun 2016 Launched for Type-2 diabetes mellitus in Myanmar (PO) (Kissei Pharmaceutical pipeline, June 2016)
  • 10 Apr 2015 No development reported - Phase-III for Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top